Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties. Advanz gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and Norway
Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against targets selected by BioNTech. Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech, as well as research funding, and will be eligible to receive development, regulatory and commercial milestone payments up to a total of more than $750 million, plus tiered royalties on global net sales.
Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round
Topas Therapeutics GmbH, today announced that the Company has successfully extended its Series B round with an additional €18 million (~$22 million) raised, bringing the total for this financing to €40 million. All of Topas’ existing investors participated in the extension.